Diabetes and liver danger: new study follows 317 patients to uncover hidden risks

NCT ID NCT07312136

ENROLLING_BY_INVITATION Knowledge-focused Sponsor: Linkoeping University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 317 adults with type 2 diabetes who were first examined between 2019 and 2023. Researchers will repeat advanced liver scans, blood tests, and body composition measurements to see how liver fat and scarring change over time. The goal is to find out who is most at risk for serious liver disease and what factors—like physical activity, sleep apnea, or genetics—drive progression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors predict who will develop serious liver problems and guide earlier, more personalized care.
What could go wrong: This is an observational follow-up study, not a treatment trial. It cannot prove that any intervention works, and results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

abdominal obesity-metabolic syndrome cirrhosis of liver Fibrosis hypertensive disorder metabolic dysfunction-associated steatotic liver disease metabolic syndrome X Obesity obesity disorder obstructive sleep apnea syndrome Overweight Sarcopenia type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED FIBROSIS CIRRHOSIS HYPERTENSION MASLD - METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE METABOLIC SYNDROME OBESITY & OVERWEIGHT OSAS (OBSTRUCTIVE SLEEP APNEAS SYNDROME) SARCOPENIA TYPE 2 DIABETES

Contacts and locations

Locations

Department of Gastroenterology and Hepatology, Linköping University Hospital

Linköping, Östergötland County, 58185, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.